BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33560766)

  • 1. Associations Between Copays, Coverage Limits for Opioid Use Disorder Medications, and Prescribing in Medicaid, 2018.
    Barenie RE; Kesselheim AS; Tsacogianis T; Fischer MA
    Med Care; 2021 Mar; 59(3):266-272. PubMed ID: 33560766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations Between Copays, Coverage Limits for Naloxone, and Prescribing in Medicaid.
    Messinger JC; Kesselheim AS; Vine SM; Fischer MA; Barenie RE
    Subst Abuse; 2022; 16():11782218221126972. PubMed ID: 36199698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiation and Receipt of Medication for Opioid Use Disorder Among Adolescents and Young Adults in 4 State Medicaid Programs in 2018: Improving Medicaid Quality Metrics.
    Lynch V; Clemans-Cope L
    Subst Use Addctn J; 2024 Jul; 45(3):434-445. PubMed ID: 38294428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design.
    Morgan JR; Quinn EK; Chaisson CE; Ciemins E; Stempniewicz N; White LF; Linas BP; Walley AY; LaRochelle MR
    Med Care; 2022 Mar; 60(3):256-263. PubMed ID: 35026792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care.
    Abraham AJ; Andrews CM; Harris SJ; Westlake MM; Grogan CM
    JAMA Health Forum; 2022 Nov; 3(11):e224001. PubMed ID: 36331441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
    Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
    JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Availability of Medications for Opioid Use Disorder in Community Mental Health Facilities.
    Cantor J; Griffin BA; Levitan B; Mendon-Plasek SJ; Stein BD; Hunter SB; Ober AJ
    JAMA Netw Open; 2024 Jun; 7(6):e2417545. PubMed ID: 38888921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contraception claims by medication for opioid use disorder prescription status among insured women with opioid use disorder, United States, 2018.
    Goyal S; Monsour M; Ko JY; Curtis KM; Whiteman MK; Coy KC; Cox S; Romero L
    Contraception; 2023 Jan; 117():67-72. PubMed ID: 36243128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the role of Section 1115 waivers on Medicaid coverage and utilization of opioid agonist therapy among substance use treatment admissions.
    Tormohlen KN; Krawczyk N; Feder KA; Riehm KE; Crum RM; Mojtabai R
    Health Serv Res; 2020 Apr; 55(2):232-238. PubMed ID: 31884703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
    Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
    JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
    Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
    J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Provider-directed marketing may increase prescribing of medications for opioid use disorder.
    Nguyen T; Andraka-Christou B; Simon K; Bradford WD
    J Subst Abuse Treat; 2019 Sep; 104():104-115. PubMed ID: 31370974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population.
    Cole ES; Drake C; DiDomenico E; Sharbaugh M; Kim JY; Nagy D; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kmiec J; Kelley D; Donohue JM
    Drug Alcohol Depend; 2021 Apr; 221():108633. PubMed ID: 33631544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.
    Hollander MAG; Chang CH; Douaihy AB; Hulsey E; Donohue JM
    Drug Alcohol Depend; 2021 Oct; 227():108927. PubMed ID: 34358766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of an office-based addiction treatment model for Medicaid enrollees: A mixed methods study.
    Treitler P; Enich M; Bowden C; Mahone A; Lloyd J; Crystal S
    J Subst Use Addict Treat; 2024 Jan; 156():209212. PubMed ID: 37935350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder.
    Dowd WN; Barch DH; Seibert JH; Mark TL
    J Subst Abuse Treat; 2022 Sep; 140():108824. PubMed ID: 35780730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
    Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
    J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
    Mauro PM; Gutkind S; Annunziato EM; Samples H
    JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions.
    Thomas CP; Stewart MT; Ledingham E; Adams RS; Panas L; Reif S
    JAMA Netw Open; 2023 Mar; 6(3):e232052. PubMed ID: 36884250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.